Delivery Order SPE2DB20D2104-SPE2DB25FMXHR
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,942.82 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,186.91 to AmerisourceBergen Drug Corp for the supply of Alfuzosin HCL ER 10 mg tablets (90-count) under a firm fixed price arrangement. The contract, which was competitively awarded with no set-aside designation, is scheduled for completion by August 11, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction within the company's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count) with a ceiling value of $4,953.94. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (120-count units) valued at $1,240.25. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by July 29, 2025, with performance to be executed from AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order represents...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $1,541.01. This is a firm fixed-price delivery order with no set-aside designation, completed competitively under open procurement requirements. The contract calls for delivery to Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. This delivery order represents a child contract...
- This contract award for $1,415.85 was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Alfuzosin HCL ER 10 mg tablets and has an ultimate completion date of October 13, 2023. The contract is a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Alfuzosin HCL ER 10 mg tablets (90-count units) with a ceiling value of $2,770.72. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation, indicating it was awarded through open competition. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,699.40 firm-fixed-price delivery order is for 4,566,716,754 units of Alfuzosin HCl ER 10 mg tablets, with a completion date of December 16, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for the supply of 4,565,371,841 units of Alfuzosin HCL ER 10 mg tablets, a prescription medication. The order is a firm fixed-price contract with a ceiling value of $8,283.44, and the period of performance extends through August 8, 2024. AmerisourceBergen, the prime contractor, will be responsible for delivering the pharmaceutical product to...
- This is a $11,307.61 delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Alfuzosin HCL ER 10 mg tablets. The award is not a set-aside contract. This delivery order appears to be part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXHRDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,123.86 to AmerisourceBergen Drug Corp for Alfuzosin HCL ER 10 mg tablets (90-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order was not issued under a set-aside program. The award represents a small-value transaction typical of routine pharmaceutical replenishment orders under the company's larger contract vehicle with DLA. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the place of performance for this award—is a major pharmaceutical distributor supplying a broad range of medications and medical supplies to support Defense Health Agency and other federal healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates its capability to meet competitive procurement requirements across multiple therapeutic domains, from specialty medications to generic drugs and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/8/25 |